Skip to content

Longitudinal Studies of the Glycoproteinoses

Longitudinal Studies of the Glycoproteinoses

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01891422
Enrollment
100
Registered
2013-07-03
Start date
2009-08-31
Completion date
2020-07-31
Last updated
2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alpha Mannosidosis, Aspartylglucosaminuria, Beta Mannosidosis, Fucosidosis, Galactosialidosis, Mucolipidosis II, Mucolipidosis III, Schindler Disease, Sialidosis

Keywords

Glycoprotein Storage Disease, Lysosomal Storage Disease, mannosidase deficiency disorders, Neuraminidase deficiency with beta-galactosidase deficiency, mucolipidoses, Oligosaccharidoses, Lysosomal Disease, Metabolic Disease, Inborn, aspartylglucosaminuria, fucosidosis, galactosialidosis, alpha mannosidosis, beta mannosidosis, mucolipidosis II, mucolipidosis III, Schindler disease, sialidosis

Brief summary

The glycoproteinoses are among the most rare and least researched of the lysosomal diseases. The diseases include aspartylglucosaminuria, fucosidosis, galactosialidosis, alpha-mannosidosis, beta-mannosidosis, mucolipidosis II, mucolipidosis III, Schindler disease, and sialidosis. Longitudinal studies of these conditions are needed in order to better define how common the diseases are, identify clinical features which could contribute to early diagnoses, detail progression of the diseases, assess the supportive therapies currently used, and identify potential treatments. Laboratory tests will evaluate metabolic and genetic defects found in participants' blood and urine samples.

Detailed description

This is a longitudinal study of 100 individuals diagnosed with any one of the nine glycoproteinoses. Because of the small number of individuals diagnosed with these diseases, participants will be strongly encouraged to be evaluated in person at a study site, but inability to travel to a study site will not exclude a person from participating. This non-interventional study will also collect medical information about participants through questionnaire, phone interviews, and review of medical records regarding the person's usual medical care, including lab testing and x-rays or other imaging studies. Participants who are evaluated at the study center will have a physical examination performed by a clinical geneticist and neuropsychological studies administered by the study psychologist. Neuropsychological studies assess intelligence, learning abilities, language skills, and ability to participate in day to day activities of life. Participants seen at the study center will have skeletal x-rays performed to evaluate the impact of the disease on the participant's bones. Every participant will complete (or have a care provider complete for them) * A questionnaire about their birth, development, and medical history * An interview with study personnel (in person or via telephone) * Follow up interviews on at least an annual basis to update the medical history Each participant will be asked to * Give a blood sample * Give a urine sample * Some participants may be asked to give a skin biopsy.

Interventions

Sponsors

Greenwood Genetic Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Be an individual of any age diagnosed with one of the following conditions * Aspartylglucosaminuria * Fucosidosis * Galactosialidosis * alpha mannosidosis * beta mannosidosis * Mucolipidosis II * Mucolipidosis III * Schindler disease * Sialidosis

Exclusion criteria

* not diagnosed with one of the nine glycoproteinoses listed above.

Design outcomes

Primary

MeasureTime frameDescription
Change in Disease Characteristics Over TimeBaseline, Year 1, Year 2, Year 3, Year 4Specific characteristics will be assessed by history and medical record review, to include: onset of disease presentation (signs and symptoms); age at presentation; timeframe of developmental milestones; milestones for educational achievement and cognitive measures; surgical procedures- when performed and outcomes; growth data over time; and indications for subspecialist care (for example cardiology, orthopedics, neurology).

Secondary

MeasureTime frameDescription
Identification of Genotype-Phenotype CorrelationBaselineMolecular and biochemical tests will be performed at subjects' baseline visits to confirm disease identity, and to identify genotype-phenotype correlations.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026